Hawaii Macula and Retina Institute Timeline of Significant Events
Important Events in Retina Research
2021
- Dr. Kokame awarded the 2021 J. Donald Gass Medal by the Macula Society for outstanding contributions in the study of macular diseases.
- “Laser Treatment After Minimized Eye Movement for Repair of Retinal Detachment” presented by Dr. Kokame at the Annual Retina Society Meeting.
- Dr. Kokame presented “Prevalence of Polypoidal Choroidal Vasculopathy and Anti-VEGF Resistance in Exudative Age-related Macular Degeneration in Caucasian Patients” at the Annual Macula Society Meeting (Virtual).
- Dr. Kokame performs the first subretinal delivery of gene therapy at Eye Surgery Center of Hawaii in November
2020
- “Loss of Characteristic Findings of PCV on B-Scan OCT after Antiangiogenic Therapy” was presented by Dr. Kokame at the Retina Society’s Annual Meeting (Virtual).
- Dr. Kokame presented “Episcleral Brachytherapy for Exudative Macular Degeneration” at the American Society of Retinal Specialists Annual Meeting (Virtual).
2019
- “Quiescence of Exudative AMD After Endophthalmitis” was presented by Dr. Kokame in Shanghai, China for the APVRS Annual Meeting.
- Dr. Kokame hosted the 8th Bi-Annual Gass Fellowship Society Meeting in San Francisco, CA
- Dr. Kokame presents important research on Anti-VEGF Resistance in PCV at Retina Society in London, UK
- APAO 2019 in Bangkok, Thailand
- Retina World Congress in Ft. Lauderdale, Florida – March 21-24
- Novartis CRTH258AUS04: Intravitreal injection of brolucizumab for persistent retinal fluid secondary to exudative macular degeneration.
2018
- Retina Consultants of Hawaii celebrates the 25th Anniversary of the Retina Center at Pali Momi with a 3-day international symposium at Halekulani Hotel – April 27-29
- Dr. James Lai and Dr. Kokame both present posters at ARVO 2018 with students in April
- Dr. Kokame presents Anti-VEGF resistance at American Ophthalmological Society in Dana Point, CA – May
- Dr. Kokame invited on the Expert Panel American Society of Retina Specialists in Vancouver, BC in July 2019
- Dr. James Lai and Dr. Kokame both present original research at the annual Retina Society Meeting in San Francisco, CA – September
- Genentech YOSEMITE: Intravitreal injection of faricimab for diabetic macular edema
2017
- Dr. Gregg Kokame presents on Treatment options for PCV at the Aspen Retinal Detachment Society in Colorado, March 2017
- Clearside Biomedical SAPPHIRE: Suprachoroidal injection of CLS-TA for Retinal Vein Occlusion
- Dr. Gregg Kokame presents four different lectures at Pan-American Association of Ophthalmology in Lima, Peru, July 2017
- In October, Dr. Kokame presented new findings on Anti-VEGF Resistance at the 50th Anniversary Retina Society Meeting in Boston, MA
- Ophthotech OPH2006: Zimura administered for polypoidal choroidal vasculopathy
- In November, Dr. Kokame hosted the 7th Bi-Annual Gass Fellowship Society Meeting in New Orleans, LA
- RCH attended American Academy of Ophthalmology where Dr. Kokame co-instructed the PCV course for the 8th consecutive year
- Dr. Kokame presented at the 11th annual Asia-Pacific Vitreo-retina Society Congress in Kuala Lumpur, Malaysia, December
2016
- Dr. Gregg Kokame presents OCT Angiography for Polypoidal Choroidal Vasculopathy at the 39th Annual Macula Society Meeting in February 2016
- HMRI’s Third ARGUS II surgery was a featured story on Japan’s FUJI TV channel on March 3, 2016
- Regeneron ONYX and RUBY: REGN910-3 for Wet AMD (9 month study Begins)
- Ohr MAKO: Topical Squalamine for Wet AMD (9 month study begins)
- Dr. Raymond Wee presents at the Ocular Imaging Conference / Western Association for Vitreoretinal Education (OIC/WAVE) in Colorado in June 2016
- Dr. Gregg Kokame presents over the Bionic Eye in Taiwan for the Retina International World Congress in July 2016
- Dr. Raymond Wee presents PCV research from HMRI at American Society of Retinal Specialists in August 2016 in San Francisco
- Dr. James Lai introduces results of HMRI’s Pearl II study results at the 49th Annual Retina Society Meeting in San Diego.
- HMRI doctor, Gregg Kokame invited to teach the PCV course during Retina Subspecialty Day in Chicago, October 2016
- Dr. Gregg Kokame traveled to Tokyo to present at the Japanese Retina and Vitreous Society in December of 2016
2015
2014
- HMRI Approved as Site for Second Sight ARGUS II Retinal Prosthesis Post-Approval Study
- Investigator Sponsored Trial (EPIC): Eylea® for Polypoidal Choroidal Vasculopathy (PCV) (Updated to 2 Year Study)
- Allergan PALM: DARPin for Diabetic Macular Edema (7 month Study Begins)
- Thrombogenics ORBIT: Jetrea Safety Assessment for Vitreomacular Adhesion (1 Year Study Begins)
- Genentech CHROMA: Lampalizumab for Dry AMD with Geographic Atrophy (2 Year Study Begins)
2013
- Acucela: Visual Cycle Modulators for Dry AMD (2 Year Study Begins)
- Investigator Sponsored Trial (EPIC): Eylea® for Polypoidal Choroidal Vasculopathy (PCV) (1 Year Study Begins)
- Lpath: iSONEP +/- Avastin, Eylea or Lucentis for Exudative Macular Degeneration (1 Year Study Begins)
2012
- FDA Approved Lucentis™ 0.3mg for the Treatment of Diabetic Macular Edema
- FDA Approves Eylea® for the Treatment of Exudative Macular Degeneration
- Allergan: REACH: DARPin for Wet-AMD (1 Year Study) Begins
- JDRF (Juvenile Diabetes Research Foundation): IDEAL: ico-007
- Barnes Retina: CRAVE: Lucentis vs Avastin for Retinal Vein Occlusion (RVO) (1 Year Study) Begins
2011
- Regeneron: VISTA: Eylea™ +/- Laser Photocoagulation Study for Diabetic Macular Edema (3-Year Study) Begins
2010
- Regeneron: VIEW1 Extension Study: Eylea® for Wet-AMD (3 Year Study) Begins
- Acucela: ENVISION CLARITY: Visual Cycle Modulators (VCM) for Dry AMD (3-Month Study) Begins
- Investigator Sponsored Trial: PEARL2: 2.0mg Lucentis™ for Polypoidal Choroidal Vasculopathy (PCV) (2-year Study) Begins
2009
- Genentech: HARBOR: 2.0mg (High-Dose) Lucentis™ for Wet-AMD (2-Year Study) Begins
- Macusight: DIAMOND: rapamycin for Diabetic Macular Edema (DME) (3-Year Study) Begins
2008
- Regeneron: VIEW1: Eylea® for Wet-AMD (2-Year) Study Begins
- Allergan: POSURDEX: Ozurdex +/- Laser Photocoagulation for Diabetic Macular Edema (DME) Study (15 Month Study Begins)
- Pfizer: QUARK: siRNA for Wet-AMD (2-Year Study) Begins
- COBALT: siRNA for Wet-AMD (2-Year Study) Begins
2007
- Genentech: RISE: Lucentis™ for Diabetic Macular Edema (DME) (3-Year Study) Begins
- Novartis: DENALI: Visudyne™ +/- Lucentis™ (2-Year Study) Begins
- Asian AMD Genetic Study Begins
2006
- FDA Approves Lucentis™ for the Treatment of Exudative Macular Degeneration
- Investigator Sponsored Trial: PEARL: Lucentis™ for Polypoidal Choroidal Vasculopathy (PCV) Study (1 Year Study)
2005
- Eyetech: EOP1012: Macugen® for Wet-AMD (2-Year Study) Begins
- Genentech: HORIZON: Extension Study for Lucentis for AMD (5-Year Study) Begins
- DRCR.net: Protocol D: Vitrectory for Diabetic Macular Edema (DME) (3-Year Study) Begins
- Eyetech: EOP1013: Macugen® for Diabetic Macular Edema (3-Year Study) Begins
- Genentech: SAILOR: Lucentis™ for Wet-AMD (1 Year Study) Begins
2004
- DRCR.net: Protocol B: Intravitreal Triamcinolone vs Laser Photocoagulation for Diabetic Macular Edema (DME) (3-Year Study) Begins
- LuEster Mertz/Novartis: VisTA: Triamcinolone +/- Visudyne PDT (2-Year Study) Begins
2003
- Genentech: MARINA Study: Lucentis for Wet-AMD (2-Year Study) Begins
- DRCR.net: Protocol A: Laser Photocoagulation for Diabetic Macular Edema (DME) (3-Year Study) Begins
2002
- FDA Approves Visudyne™ for the Treatment of Exudative Macular Degeneration
- Genentech: FOCUS Study: Lucentis +/- Visudyne™ Photodynamic Therapy for Wet-AMD (2-year Study) Begins
2001
- Eli Lilly PKC Study: Oral Medicaion for Diabetic Retinopathy (4-year Study) Begins
1993 – Research at HMRI begins under the direction of Gregg T. Kokame, MD
